TrialOpen forum infectious diseases2024

4CMenB Breadth of Immune Response, Immunogenicity, and Safety: Results From a Phase 3 Randomized, Controlled, Observer Blind Study in Adolescents and Young Adults.

Terry Nolan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.